Press Room

Webinar Series: Amorphous Solid Dispersions by Spray Drying: From Early Formulation to Commercial Lifecycle Management

Start
Tuesday, February 28, 2023 - 16:00
End
Thursday, April 20, 2023 - 17:00
Location: online
Webinar Series Spray Drying - SEM image of a particle in a dark green background

Hovione presents a new comprehensive three-part webinar series on "Amorphous Solid Dispersions by Spray Drying: From Early Formulation to Commercial Lifecycle Management" starting February 28, 2023.

Over the course of this series, Hovione experts will guide you through the complete journey of amorphous solid dispersions (ASDs), starting from the early formulation stage to process development and scale-up, and finally to commercial reality and lifecycle management of ASDs. 
As an experienced manufacturer of ASDs by spray drying for the pharmaceutical industry, Hovione will be able to share its extensive knowledge and experience. Furthermore, the featured experts will be available to answer your questions during a live Q&A.

 

Key Learnings for the Webinar Series

  • Gain knowledge on designing a successful formulation for Amorphous Solid Dispersions produced by Spray Drying
  • Discover how to develop a robust process at lab scale and assure a successful scale-up
  • Learn how to use a model-based methodology to establish the design space and a commercial process
  • Understand what to consider during the Lifecycle Management of a commercial Amorphous Solid Dispersion by Spray Drying 

 

SESSION 1 (On-demand)
Evaluating the Best Formulations for Amorphous Solid Dispersions by Spray Drying

Register Now to join us | Hovione

 

SESSION 2 (On-demand)
ASDs by Spray Drying: Process Development & Scale-Up

Register Now to join us | Hovione

 

SESSION 3 (On-demand)
Commercial Reality and Lifecycle Management of ASDs

Register Now to join us | Hovione

 

 

Do you have a challenging project?

get in touch with us click here | Hovione

Schedule your individual meeting at the upcoming tradeshows and conferences in Berlin, Boston, Orlando, Barcelona, Delhi or Edinburgh.

 

 

 

Also in the Press Room

See All

Hovione’s Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At Hovione we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook – “Trends in Formulation”.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how Hovione is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa’s full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal – Hovione, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, Hovione joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At Hovione, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of Hovione. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” Hovione will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with Hovione’s sustainability ambitions.  Hovione remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024